Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-II STUDIES OF RECOMBINANT HUMAN INTERLEUKIN-4 IN ADVANCED RENAL-CANCER AND MALIGNANT-MELANOMA
Autore:
MARGOLIN K; ARONSON FR; SZNOL M; ATKINS MB; GUCALP R; FISHER RI; SUNDERLAND M; DOROSHOW JH; ERNEST ML; MIER JW; DUTCHER JP; GAYNOR ER; WEISS GR;
Indirizzi:
CITY HOPE NATL MED CTR,DEPT MED ONCOL,1500 E DUARTE RD DUARTE CA 91010 UNIV CALIF SAN FRANCISCO SAN FRANCISCO CA 94143 NCI,CANC THERAPY PROGRAM BETHESDA MD 00000 TUFTS UNIV,NEW ENGLAND MED CTR BOSTON MA 02111 MONTEFIORE MED CTR,ALBERT EINSTEIN CANC CTR BRONX NY 10467 LOYOLA UNIV,STRITCH SCH MED CHICAGO IL 00000 UNIV TEXAS,AUDIE MURPHY VET ADM HOSP,HLTH SCI CTR SAN ANTONIO TX 00000
Titolo Testata:
Journal of immunotherapy with emphasis on tumor immunology
fascicolo: 2, volume: 15, anno: 1994,
pagine: 147 - 153
SICI:
1067-5582(1994)15:2<147:PSORHI>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-NECROSIS-FACTOR; GAMMA-INTERFERON; CELL-GROWTH; LYMPHOCYTES; ALPHA; IL-4; PROLIFERATION; EXPRESSION; MONOCYTES; INVITRO;
Keywords:
INTERLEUKIN-4; RENAL CANCER; MALIGNANT MELANOMA; CYTOKINES; IMMUNOTHERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
23
Recensione:
Indirizzi per estratti:
Citazione:
K. Margolin et al., "PHASE-II STUDIES OF RECOMBINANT HUMAN INTERLEUKIN-4 IN ADVANCED RENAL-CANCER AND MALIGNANT-MELANOMA", Journal of immunotherapy with emphasis on tumor immunology, 15(2), 1994, pp. 147-153

Abstract

Interleukin (IL)-4 is a pluripotent cytokine that stimulates proliferation of activated T-cells and has antineoplastic activity against human renal tumors in animal systems. In phase I trials, IL-4 could be tolerated at doses up to 20 mu g/kg, with dose-limiting toxicities consisting of fever, fluid retention, nasal congestion, and mucositis. We report the results of two separate Phase II trials of IL-4 in 30 patients with metastatic malignant melanoma and 19 patients with advanced renal cancer. IL-4 was administered intravenously every 8 h for 14 dosesin two 5-day courses separated by a 9-day interval. The first 27 patients were treated at a dose of 800 mu g/m(2), but after three of thesepatients developed cardiac toxicities, the dose was decreased to 600 mu g/m(2). One complete response occurred in a patient with metastaticmelanoma (duration greater than or equal to 30 months). No responses were seen among the patients with renal cancer. The most frequent sideeffects were fever, nausea, malaise, nasal congestion, and diarrhea. Reversible hepatic and renal dysfunction were also common. Hypotensionwas infrequent, but transient weight gain due to fluid retention was common. The major life-threatening toxicities were cardiac and gastrointestinal. Suspected cardiac ischemia was observed in two patients, pericarditis in one, and arrhythmias in two. Three patients had major upper gastrointestinal bleeding without evidence of local tumor. We conclude that IL-4, when given as a single agent on this schedule at maximum tolerated dose, does not possess meaningful activity in renal cancer or melanoma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 10:24:11